Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › aflibercept

aflibercept

13 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of aflibercept

64 trials tracked of aflibercept: 40 in phase 3 or 4 and 22 with published results. The most-cited published study has 777 citations.

64Trials tracked
40Phase 3 & 4
0Recruiting
22With published results
Phase distribution
Phase 4 10 Phase 3 30 Phase 2 23 Other / NA 1
  1. Phase 3 A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA) Completed · 777 cited
  2. Phase 4 Aflibercept in Polypoidal Choroidal Vasculopathy Completed · 275 cited
  3. Phase 4 Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration Completed · 256 cited
  4. Phase 3 A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE) Completed · 227 cited
  5. Phase 3 Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Completed · 215 cited
  6. Phase 3 A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE) Completed · 175 cited
Show 44 more trials
  1. Phase 3 A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema Completed · 175 cited
  2. Phase 3 Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease Completed · 135 cited
  3. Phase 3 A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion Completed · 113 cited
  4. Phase 3 A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion Completed · 91 cited
  5. Phase 4 Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept Completed · 74 cited
  6. Phase 3 Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema Completed · 42 cited
  7. Phase 4 Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial Completed · 39 cited
  8. Phase 4 Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO Completed · 37 cited
  9. Phase 4 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO Completed · 31 cited
  10. Phase 4 Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab Completed · 21 cited
  11. Phase 3 Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME) Completed · 18 cited
  12. Phase 3 Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients Completed · 16 cited
  13. Phase 3 Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement Completed · 15 cited
  14. Phase 3 Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied Completed · 15 cited
  15. Phase 3 Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD) Completed · 4 cited
  16. Phase 3 A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD] Completed
  17. Phase 4 Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy Completed
  18. Phase 4 Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD Completed
  19. Phase 4 A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema Completed
  20. Phase 3 Colorectal Cancer Metastatic Completed
  21. Phase 3 Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema Completed
  22. Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity Completed
  23. Phase 3 A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD) Completed
  24. Phase 3 A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema Completed
  25. Phase 3 A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) Completed
  26. Phase 3 A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) Completed
  27. Phase 3 To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema Completed
  28. Phase 3 A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD) Completed
  29. Phase 3 A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Completed
  30. Phase 3 VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration) Completed
  31. Phase 3 Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer Completed
  32. Phase 3 Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen Completed
  33. Phase 3 Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites Completed
  34. Phase 3 A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy Completed
  35. Phase 2 Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE) Completed
  36. Phase 2 A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration Completed
  37. Phase 2 Role of Intravitreal Aflibercept Injection for the Treatment of Radiation Maculopathy Completed
  38. Phase 2 A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD Completed
  39. Phase 2 A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema Completed
  40. Phase 2 VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer Completed
  41. Phase 2 AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites Completed
  42. Phase 2 A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD Completed
  43. Phase 2 Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy Completed
  44. Phase 2 5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer Completed

Showing the 50 most-cited and recently-updated of 64 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Meta-analysis: Anti-VEGF biosimilars show equivalent efficacy, safety to reference agents in nAMD
Oncology Meta-analysis
Meta-analysis: Anti-VEGF biosimilars show equivalent efficacy, safety to reference agents in nAMD Can cheaper eye drugs work as well as expensive ones? A major review says yes for vision loss in older adults
A meta-analysis of 17 RCTs (n=6694) found no clinically meaningful differences in BCVA improvement at 12 weeks (MD=-0.42, p=0.17) or endpoin…
Cheaper eye drug copies work just as well as expensive originals for treating vision loss in older adults, a major review confirms.
Mar 30, 2026